Literature DB >> 21742842

Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneously.

Rosa María Wong-Chew1, Miguel Leonardo García-León, Bogart Espinosa-Torres Torrija, Brenda Hernández-Pérez, Lino E Cardiel-Marmolejo, Judy A Beeler, Susette Audet, José Ignacio Santos-Preciado.   

Abstract

BACKGROUND: A 30-second aerosol measles vaccination successfully primes children 12 months of age and older but is poorly immunogenic when given to 9-month-old children. We examined the immune responses when increasing the duration to aerosol exposure in 9-month-olds.
METHODS: One hundred and thirteen healthy 9-month-old children from Mexico City were enrolled; 58 received aerosol EZ measles vaccine for 2.5 minutes and 55 subcutaneously. Measles-specific neutralizing antibodies and cellular responses were measured before and at 3 and 6 months postimmunization.
RESULTS: Adaptive immunity was induced in 97% after aerosol and 98% after subcutaneous administration. Seroconversion rates and GMCs were 95% and 373 mIU/mL (95% confidence interval [CI], 441-843) following aerosol vaccination and 91% and 306 mIU/mL (95% CI, 367-597) after subcutaneous administration at 3 months. The percentage of children with a measles-specific stimulation index ≥3 was 45% and 60% in the aerosol versus 55% and 59% in the subcutaneous group at 3 and 6 months, respectively. CD8 memory cell frequencies were higher in the aerosol group at 3 months compared with the subcutaneous group. Adverse reactions were comparable in both groups.
CONCLUSIONS: Increasing exposure time to aerosol measles vaccine elicits immune responses that are comparable to those seen when an equivalent dose is administered by the subcutaneous route in 9-month-old infants.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21742842      PMCID: PMC3165943          DOI: 10.1093/infdis/jir278

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  Additional evidence that the cell-associated immune system is the primary host defense against measles (rubeola).

Authors:  J C Ruckdeschel; K D Graziano; M R Mardiney
Journal:  Cell Immunol       Date:  1975-05       Impact factor: 4.868

2.  Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination.

Authors:  N Bautista-López; B J Ward; E Mills; D McCormick; N Martel; S Ratnam
Journal:  Vaccine       Date:  2000-01-31       Impact factor: 3.641

3.  Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months.

Authors:  H Gans; L Yasukawa; M Rinki; R DeHovitz; B Forghani; J Beeler; S Audet; Y Maldonado; A M Arvin
Journal:  J Infect Dis       Date:  2001-08-22       Impact factor: 5.226

4.  [Measles vaccination by the aerosol method in Mexico].

Authors:  J Fernández-de Castro; J Kumate-Rodríguez; J Sepúlveda; J M Ramírez-Isunza; J L Valdespino-Gómez
Journal:  Salud Publica Mex       Date:  1997 Jan-Feb

5.  Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination.

Authors:  B J Ward; N Boulianne; S Ratnam; M C Guiot; M Couillard; G De Serres
Journal:  J Infect Dis       Date:  1995-12       Impact factor: 5.226

6.  Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.

Authors:  Hayley A Gans; Linda L Yasukawa; Amanda Alderson; Mary Rinki; Ross DeHovitz; Judith Beeler; Susette Audet; Yvonne Maldonado; Ann M Arvin
Journal:  J Infect Dis       Date:  2004-05-26       Impact factor: 5.226

7.  Additional evidence against measles vaccine administration to infants less than 12 months of age: altered immune response following active/passive immunization.

Authors:  J Wilkins; P F Wehrle
Journal:  J Pediatr       Date:  1979-06       Impact factor: 4.406

8.  Role of virus strain in conventional and enhanced measles plaque neutralization test.

Authors:  P Albrecht; K Herrmann; G R Burns
Journal:  J Virol Methods       Date:  1981-12       Impact factor: 2.014

9.  Successful immunization of infants with and without maternal antibody by aerosolized measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response.

Authors:  A B Sabin; A Flores Arechiga; J Fernández de Castro; P Albrecht; J L Sever; I Shekarchi
Journal:  JAMA       Date:  1984-05-11       Impact factor: 56.272

10.  Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines.

Authors:  A B Sabin; A Flores Arechiga; J Fernández de Castro; J L Sever; D L Madden; I Shekarchi; P Albrecht
Journal:  JAMA       Date:  1983-05-20       Impact factor: 56.272

View more
  4 in total

1.  A correlation of measles specific antibodies and the number of plasmacytoid dendritic cells is observed after measles vaccination in 9 month old infants.

Authors:  Miguel L García-León; Laura C Bonifaz; Bogart Espinosa-Torres; Brenda Hernández-Pérez; Lino Cardiel-Marmolejo; José I Santos-Preciado; Rosa M Wong-Chew
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; V Shane Pankratz; Richard B Kennedy; Robert M Jacobson; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

Review 3.  Perspective on Global Measles Epidemiology and Control and the Role of Novel Vaccination Strategies.

Authors:  Melissa M Coughlin; Andrew S Beck; Bettina Bankamp; Paul A Rota
Journal:  Viruses       Date:  2017-01-19       Impact factor: 5.048

4.  Needle-free delivery of measles virus vaccine to the lower respiratory tract of non-human primates elicits optimal immunity and protection.

Authors:  Rik L de Swart; Rory D de Vries; Linda J Rennick; Geert van Amerongen; Stephen McQuaid; R Joyce Verburgh; Selma Yüksel; Alwin de Jong; Ken Lemon; D Tien Nguyen; Martin Ludlow; Albert D M E Osterhaus; W Paul Duprex
Journal:  NPJ Vaccines       Date:  2017-08-01       Impact factor: 7.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.